PMID- 29556575
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240320
IS  - 2452-1094 (Print)
IS  - 2452-1094 (Electronic)
IS  - 2452-1094 (Linking)
VI  - 3
IP  - 1
DP  - 2018 Jan-Mar
TI  - Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation 
      therapy.
PG  - 19-24
LID - 10.1016/j.adro.2017.09.004 [doi]
AB  - PURPOSE: Breast fibrosis is a common late effect after therapeutic irradiation 
      that can result in pain, poor cosmesis, and functional impairment. Randomized 
      trials have demonstrated that radiation fibrosis may be preventable with a 
      medication regimen of pentoxifylline and vitamin E. This study investigates 
      patient compliance with pentoxifylline therapy while examining possible 
      correlations to compliance. METHODS AND MATERIALS: We identified 90 patients who 
      were prescribed pentoxifylline (400 mg 3 times daily) and vitamin E (400 IU once 
      daily) after adjuvant breast radiation. A retrospective cohort study was 
      conducted using medical record analysis. Data were collected, including patient 
      age, comorbid conditions, concurrent medications, duration of pentoxifylline and 
      vitamin E therapy, dose adjustments, patient-reported side effects, and cause for 
      discontinuation. A multivariate analysis of the correlation between medication 
      compliance and these categorical variables was assessed with a chi(2) analysis of 
      independence. RESULTS: Patient compliance with pentoxifylline and vitamin E 
      therapy was found to be poor in 33 of 87 patients (38%) in the cohort, 
      necessitating either dose reductions or discontinuation of therapy. There was a 
      statistically significant correlation between concurrent antiemetic therapy and 
      successful completion of pentoxifylline regimen. Of those on antiemetic therapy, 
      89% completed pentoxifylline as prescribed versus 48% of those without 
      antiemetics (P < .001). There was a statistically significant correlation between 
      concurrent proton pump inhibitor (PPI) therapy and discontinuation of 
      pentoxifylline. Of those on PPI therapy, 33% completed pentoxifylline versus 81% 
      of those not on PPIs (P < .001). All other variables examined were not 
      significantly correlated with compliance. CONCLUSIONS: Patient compliance with 
      pentoxifylline appears to be worse in clinical practice compared with previously 
      published studies. Nausea was the most frequently reported indication for 
      treatment modification or discontinuation. Concurrent antiemetic therapy was 
      correlated with strong regimen compliance, but concurrent PPI therapy was 
      correlated with poor compliance, independent of comorbid conditions.
FAU - Famoso, Justin M
AU  - Famoso JM
AD  - Department of Radiation Oncology, The University of Arizona, Tucson, Arizona.
FAU - Laughlin, Brady
AU  - Laughlin B
AD  - University of Arizona College of Medicine, Tucson, Arizona.
FAU - McBride, Ali
AU  - McBride A
AD  - Department of Hematology/Oncology, The University of Arizona Cancer Center, 
      Tucson, Arizona.
FAU - Gonzalez, Victor J
AU  - Gonzalez VJ
AD  - Department of Radiation Oncology, The University of Arizona, Tucson, Arizona.
LA  - eng
PT  - Journal Article
DEP - 20170908
PL  - United States
TA  - Adv Radiat Oncol
JT  - Advances in radiation oncology
JID - 101677247
PMC - PMC5856981
EDAT- 2018/03/21 06:00
MHDA- 2018/03/21 06:01
PMCR- 2017/09/08
CRDT- 2018/03/21 06:00
PHST- 2017/03/28 00:00 [received]
PHST- 2017/08/22 00:00 [revised]
PHST- 2017/09/06 00:00 [accepted]
PHST- 2018/03/21 06:00 [entrez]
PHST- 2018/03/21 06:00 [pubmed]
PHST- 2018/03/21 06:01 [medline]
PHST- 2017/09/08 00:00 [pmc-release]
AID - S2452-1094(17)30190-2 [pii]
AID - 10.1016/j.adro.2017.09.004 [doi]
PST - epublish
SO  - Adv Radiat Oncol. 2017 Sep 8;3(1):19-24. doi: 10.1016/j.adro.2017.09.004. 
      eCollection 2018 Jan-Mar.